Kyprolis® (carfilzomib) – New Warning

- The FDA approved a new update to the *Warnings and Precautions* section of the Kyprolis (carfilzomib) drug label regarding fatal or serious cases of hemorrhage.

- Kyprolis is a proteasome inhibitor that is indicated:

  - In combination with dexamethasone or with Revlimid® (lenalidomide) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  - As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

- Hemorrhagic events have included gastrointestinal, pulmonary, and intracranial hemorrhage and epistaxis. The bleeding can be spontaneous, and intracranial hemorrhage has occurred without trauma. Hemorrhage has been reported in patients having either low or normal platelet counts. Hemorrhage has also been reported in patients who were not on antiplatelet therapy or anticoagulation.

  - Physicians should promptly evaluate patients for signs and symptoms of blood loss, and reduce or withhold the dose as appropriate.

- Other warnings and precautions of Kyprolis include cardiac toxicities, acute renal failure, tumor lysis syndrome, pulmonary toxicity, pulmonary hypertension, dyspnea, hypertension, venous thrombosis, infusion reactions, thrombocytopenia, hepatic toxicity and hepatic failure, thrombotic microangiopathy, posterior reversible encephalopathy syndrome, and embryo-fetal toxicity.